Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Orchestra BioMed Holdings ( (OBIO) ) has issued an announcement.
On January 12, 2026, Orchestra BioMed announced it expects to receive up to $21 million in cash proceeds following the January 9, 2026 closing of Haemonetics Corporation’s acquisition of its long-held strategic investment Vivasure Medical, an Ireland-based developer of bioabsorbable, large-bore percutaneous vessel closure technology. Orchestra BioMed anticipates $11 million of this amount will be realized in 2026 through an upfront payment of about $5 million and a first milestone payment of about $6 million, with additional consideration tied to future revenue earnouts, underscoring the financial value and strategic validation of its partnership-driven device development model and strengthening its position as an innovation partner to larger medtech players.
The most recent analyst rating on (OBIO) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Orchestra BioMed Holdings stock, see the OBIO Stock Forecast page.
Spark’s Take on OBIO Stock
According to Spark, TipRanks’ AI Analyst, OBIO is a Neutral.
Orchestra BioMed’s overall stock score is primarily impacted by its weak financial performance, characterized by high leverage and negative profit margins. However, positive corporate events, including strategic partnerships and significant financing, provide a strong foundation for future growth. The technical analysis presents a mixed outlook, while valuation remains a concern due to unprofitability.
To see Spark’s full report on OBIO stock, click here.
More about Orchestra BioMed Holdings
Orchestra BioMed Holdings is a biomedical innovation company that advances high-impact cardiovascular technologies through strategic collaborations with large medical device manufacturers. Its two flagship product candidates are AVIM Therapy, a pacemaker-delivered bioelectronic treatment for uncontrolled hypertension developed in partnership with Medtronic, and the Virtue Sirolimus AngioInfusion Balloon for drug delivery in atherosclerotic artery disease; both have FDA Breakthrough Device Designation and target multi-billion-dollar global markets.
Average Trading Volume: 291,319
Technical Sentiment Signal: Buy
Current Market Cap: $273.3M
See more data about OBIO stock on TipRanks’ Stock Analysis page.